Chronic Spontaneous Urticaria (CSU) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Chronic Spontaneous Urticaria (CSU) Market Outlook
Thelansis’s “Chronic Spontaneous
Urticaria (CSU) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Chronic Spontaneous Urticaria (CSU)
treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Chronic
Spontaneous Urticaria (CSU) Overview
Chronic
spontaneous urticaria (CSU), also called chronic idiopathic urticaria, is
characterized by the occurrence of urticaria for 6 weeks or longer without
identifiable specific triggers. The average duration of CSU is frequently
reported as 5 years, but it may be longer in more severe cases, specifically in
patients with concurrent angioedema. Patients with chronic urticaria (used as a
proxy for CSU) experience substantial health-related quality of life (HRQoL)
and productivity impairments and increased psychological comorbidities relative
to patients without chronic urticaria. CSU is the spontaneous development of
signs and symptoms with no known specific trigger. CSU and CIndU may coexist in
the same patient. Overall, urticaria is classified as an acute or chronic form
based on the duration of illness. Chronic urticaria is diagnosed when the
disease has been continuously or intermittently present for at least 6 weeks.
The chronic and acute forms of urticaria differ in etiology, pathophysiology,
and the underlying mechanism.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment